USA - NASDAQ:SDGR - US80810D1037 - Common Stock
The current stock price of SDGR is 22.52 USD. In the past month the price increased by 16.68%. In the past year, price increased by 27.38%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 39.33 | 48.03B | ||
| DOCS | DOXIMITY INC-CLASS A | 44.86 | 12.52B | ||
| WAY | WAYSTAR HOLDING CORP | 35.11 | 7.44B | ||
| HTFL | HEARTFLOW INC | N/A | 3.16B | ||
| CERT | CERTARA INC | 25.84 | 2.03B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.67B | ||
| PHR | PHREESIA INC | N/A | 1.41B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 11.29 | 1.37B | ||
| CTEV | CLARITEV CORP | N/A | 1.15B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.07B | ||
| EVH | EVOLENT HEALTH INC - A | N/A | 917.75M | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | N/A | 909.88M |
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 891 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
SCHRODINGER INC
1540 Broadway, 24th Floor
New York City NEW YORK 10036 US
CEO: Ramy Farid
Employees: 891
Phone: 15032991150
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 891 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The firm's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
The current stock price of SDGR is 22.52 USD. The price increased by 2.55% in the last trading session.
SDGR does not pay a dividend.
SDGR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
SCHRODINGER INC (SDGR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.48).
The Revenue of SCHRODINGER INC (SDGR) is expected to grow by 23.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
SCHRODINGER INC (SDGR) has a market capitalization of 1.66B USD. This makes SDGR a Small Cap stock.
ChartMill assigns a technical rating of 6 / 10 to SDGR. When comparing the yearly performance of all stocks, SDGR is one of the better performing stocks in the market, outperforming 74.6% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to SDGR. No worries on liquidiy or solvency for SDGR as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months SDGR reported a non-GAAP Earnings per Share(EPS) of -2.48. The EPS increased by 10.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.35% | ||
| ROE | -52.89% | ||
| Debt/Equity | 0 |
16 analysts have analysed SDGR and the average price target is 28.67 USD. This implies a price increase of 27.32% is expected in the next year compared to the current price of 22.52.
For the next year, analysts expect an EPS growth of 7.29% and a revenue growth 23.48% for SDGR